Penelope J Hallett

List of Publications by Citations

Source: https://exaly.com/author-pdf/6634668/penelope-j-hallett-publications-by-citations.pdf
Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

45 papers	3,143 citations	30 h-index	46 g-index
46 ext. papers	3,652 ext. citations	8.2 avg, IF	5.06 L-index

#	Paper	IF	Citations
45	Differentiated Parkinson patient-derived induced pluripotent stem cells grow in the adult rodent brain and reduce motor asymmetry in Parkinsonian rats. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 15921-6	11.5	375
44	Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. *Nature Medicine*, **2008**, 14, 507-9	50.5	355
43	Successful function of autologous iPSC-derived dopamine neurons following transplantation in a non-human primate model of Parkinson's disease. *Cell Stem Cell*, **2015**, 16, 269-74	18	214
42	Rationale for and use of NMDA receptor antagonists in Parkinson's disease **2004**, 102, 155-74		187
41	Improved cell therapy protocols for Parkinson's disease based on differentiation efficiency and safety of hESC-, hiPSC-, and non-human primate iPSC-derived dopaminergic neurons. *Stem Cells*, **2013**, 31, 1548-62	5.8	168
40	Dopamine D1 activation potentiates striatal NMDA receptors by tyrosine phosphorylation-dependent subunit trafficking. *Journal of Neuroscience*, **2006**, 26, 4690-700	6.6	167
39	Progressive decline of glucocerebrosidase in aging and Parkinson's disease. *Annals of Clinical and Translational Neurology*, **2015**, 2, 433-8	5.3	122
38	Long-term health of dopaminergic neuron transplants in Parkinson's disease patients. *Cell Reports*, **2014**, 7, 1755-61	10.6	112
37	Glucocerebrosidase gene therapy prevents -synucleinopathy of midbrain dopamine neurons. *Neurobiology of Disease*, **2015**, 82, 495-503	7.5	88
36	Striatal histone modifications in models of levodopa-induced dyskinesia. *Journal of Neurochemistry*, **2008**, 106, 486-94	6	82
35	The Toll-like receptor-3 agonist polyinosinic:polycytidylic acid triggers nigrostriatal dopaminergic degeneration. *Journal of Neuroscience*, **2010**, 30, 16091-101	6.6	80
34	Sustained Systemic Glucocerebrosidase Inhibition Induces Brain -Synuclein Aggregation, Microglia and Complement C1q Activation in Mice. *Antioxidants and Redox Signaling*, **2015**, 23, 550-64	8.4	79
33	Inhibition of the dopamine D1 receptor signaling by PSD-95. *Journal of Biological Chemistry*, **2007**, 282, 15778-89	5.4	76
32	Biochemical fractionation of brain tissue for studies of receptor distribution and trafficking. *Current Protocols in Neuroscience*, **2008**, Chapter 1, Unit 1.16	2.7	70
31	-Synuclein overexpressing transgenic mice show internal organ pathology and autonomic deficits. *Neurobiology of Disease*, **2012**, 47, 258-67	7.5	68
30	Progressive axonal transport and synaptic protein changes correlate with behavioral and neuropathological abnormalities in the heterozygous Q175 KI mouse model of Huntington's disease. *Human Molecular Genetics*, **2014**, 23, 4510-27	5.6	62
29	PSD-95 uncouples dopamine-glutamate interaction in the D1/PSD-95/NMDA receptor complex. *Journal of Neuroscience*, **2009**, 29, 2948-60	6.6	61

28	Synaptic recruitment of AMPA glutamate receptor subunits in levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate. *Synapse*, **2010**, 64, 177-80	2.4	61
27	Widespread neuron-specific transgene expression in brain and spinal cord following synapsin promoter-driven AAV9 neonatal intracerebroventricular injection. *Neuroscience Letters*, **2014**, 576, 73-8	3.3	57
26	Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson's disease. *Molecular Neurodegeneration*, **2019**, 14, 40	19	56
25	Glycosphingolipid levels and glucocerebrosidase activity are altered in normal aging of the mouse brain. *Neurobiology of Aging*, **2018**, 67, 189-200	5.6	50
24	Fibroblast Biomarkers of Sporadic Parkinson's Disease and LRRK2 Kinase Inhibition. *Molecular Neurobiology*, **2016**, 53, 5161-77	6.2	48
23	Enhanced ubiquitin-dependent degradation by Nedd4 protects against -synuclein accumulation and toxicity in animal models of Parkinson's disease. *Neurobiology of Disease*, **2014**, 64, 79-87	7.5	46
22	Functional enhancement and protection of dopaminergic terminals by RAB3B overexpression. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 22474-9	11.5	41
21	The glycoprotein GPNMB is selectively elevated in the substantia nigra of Parkinson's disease patients and increases after lysosomal stress. *Neurobiology of Disease*, **2018**, 120, 1-11	7.5	39
20	Lipid and immune abnormalities causing age-dependent neurodegeneration and Parkinson's disease. *Journal of Neuroinflammation*, **2019**, 16, 153	10.1	39
19	A Nurr1 agonist causes neuroprotection in a Parkinson's disease lesion model primed with the toll-like receptor 3 dsRNA inflammatory stimulant poly(I:C). *PLoS ONE*, **2015**, 10, e0121072	3.7	39
18	Development of histocompatible primate-induced pluripotent stem cells for neural transplantation. *Stem Cells*, **2011**, 29, 1052-63	5.8	37
17	Transcript expression levels of full-length alpha-synuclein and its three alternatively spliced variants in Parkinson's disease brain regions and in a transgenic mouse model of alpha-synuclein overexpression. *Molecular and Cellular Neurosciences*, **2012**, 49, 230-9	4.8	35
16	Neurite Collapse and Altered ER Ca Control in Human Parkinson Disease Patient iPSC-Derived Neurons with LRRK2 G2019S Mutation. *Stem Cell Reports*, **2019**, 12, 29-41	8	33
15	Mitochondrial clearance and maturation of autophagosomes are compromised in LRRK2 G2019S familial Parkinson's disease patient fibroblasts. *Human Molecular Genetics*, **2019**, 28, 3232-3243	5.6	30
14	The blood-brain barrier is intact after levodopa-induced dyskinesias in parkinsonian primates--evidence from in vivo neuroimaging studies. *Neurobiology of Disease*, **2009**, 35, 348-51	7.5	26
13	Striatal delta opioid receptor binding in experimental models of Parkinson's disease and dyskinesia. *Movement Disorders*, **2007**, 22, 28-40	7	21
12	Advantages and Recent Developments of Autologous Cell Therapy for Parkinson's Disease Patients. *Frontiers in Cellular Neuroscience*, **2020**, 14, 58	6.1	20
11	Lipid-dependent deposition of alpha-synuclein and Tau on neuronal Secretogranin II-positive vesicular membranes with age. *Scientific Reports*, **2018**, 8, 15207	4.9	19

10	Splice-Switching Antisense Oligonucleotides Reduce LRRK2 Kinase Activity in Human LRRK2 Transgenic Mice. *Molecular Therapy - Nucleic Acids*, **2020**, 21, 623-635	10.7	18
9	Cell type-specific lipid storage changes in Parkinson's disease patient brains are recapitulated by experimental glycolipid disturbance. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 27646-27654	11.5	17
8	Novel Results and Concepts Emerging From Lipid Cell Biology Relevant to Degenerative Brain Aging and Disease. *Frontiers in Neurology*, **2019**, 10, 1053	4.1	12
7	ALS-associated peripherin spliced transcripts form distinct protein inclusions that are neuroprotective against oxidative stress. *Experimental Neurology*, **2014**, 261, 217-29	5.7	9
6	Upregulating β-hexosaminidase activity in rodents prevents β-synuclein lipid associations and protects dopaminergic neurons from β-synuclein-mediated neurotoxicity. *Acta Neuropathologica Communications*, **2020**, 8, 127	7.3	6
5	Seq-ing Markers of Midbrain Dopamine Neurons. *Cell Stem Cell*, **2017**, 20, 11-12	18	5
4	Fibroblasts from idiopathic Parkinson's disease exhibit deficiency of lysosomal glucocerebrosidase activity associated with reduced levels of the trafficking receptor LIMP2. *Molecular Brain*, **2021**, 14, 16	4.5	5
3	Experimental studies of mitochondrial and lysosomal function in in vitro and in vivo models relevant to Parkinson's disease genetic risk. *International Review of Neurobiology*, **2020**, 154, 279-302	4.4	3
2	No evidence for disease-like processes in fetal transplants. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, E104; author reply E105	11.5	2
1	Glycosphingolipid metabolism and its role in ageing and Parkinson's disease. *Glycoconjugate Journal*, **2021**, 1	3	2